

The State of New Hampshire Insurance Department 21 South Fruit St, Suite 14 Concord, NH 03301

6/18/2021

Sent via E-mail: doi.healthcareanalytics@ins.nh.gov

Subject: New Drug Introduction Notification pursuant to HB 703 (Bulletin dated 4/2/2020)

To the State of New Hampshire Insurance Department:

Persuant to HB 703, Puma Biotechnology, Inc. ("Puma") hereby provides, to the State of NH Insurance Department, a new high-cost drug notice for Nerlynx (NDC 70437-0240-33).

• Nerlynx (NDC 70437-0240-33) - (neratinib) became commercially available on June 21, 2021.

If you have any further questions, please do not hesitate to contact me.

Regards,

Michael Flinn

Director, Contracting Trade and Distribution

Puma Biotechnology, Inc.

701 Gateway Blvd., 5th Floor

South San Francisco, CA 94080

Mobile (650) 515-2160

Office (424)248-6500 ext 3093

mflinn@pumabiotechnology.com